Company Description
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company.
The company’s OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences.
It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury.
In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body.
Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jul 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 94 |
| CEO | Mahesh Karande |
Contact Details
Address: 20 Acorn Park Drive Cambridge, Massachusetts 02140 United States | |
| Phone | 617 949 4360 |
| Website | omegatherapeutics.com |
Stock Details
| Ticker Symbol | OMGA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001850838 |
| CUSIP Number | 68217N105 |
| ISIN Number | US68217N1054 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mahesh Karande | President, Chief Executive Officer and Board Director |
| Dr. David A. Berry M.D., Ph.D. | Founder |
| Barbara Y. Chan | Principal Financial Office, Principal Accounting Officer and Chief Accounting Officer |
| Eva Stroynowski | Senior Vice President of Investor Relations and Corporate Affairs |
| Anthony Mullin | Chief People Officer |
| Charles O'Donnell Ph.D. | Vice President and Head of Computational Genomics and Data Sciences |
| Dr. Kaan Certel Ph.D. | Chief Business Officer |
| Lisamarie Fahy | Senior Vice President of Clinical Development Operations |
| Dr. Jennifer Nelson Ph.D. | Senior Vice President of Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 4, 2024 | 8-K | Current Report |
| Aug 30, 2024 | 8-K | Current Report |
| Aug 6, 2024 | 10-Q | Quarterly Report |
| Aug 6, 2024 | 8-K | Current Report |
| Jun 24, 2024 | 8-K | Current Report |
| May 30, 2024 | 8-K/A | [Amend] Current report |
| May 30, 2024 | 8-K | Current Report |
| May 6, 2024 | 10-Q | Quarterly Report |
| May 6, 2024 | 8-K | Current Report |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |